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Abstract
Background: Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous disorder that can be
an autosomal-dominant, autosomal-recessive, or X-linked disease. The most common autosomal-dominant form of
the disease derives from mutations in the SPAST gene.
Methods: The aim of this study was to analyze 49 patients diagnosed with HSP from the Estonian population for
sequence variants of the SPAST gene and to describe the associated phenotypes. Healthy control individuals (n =
100) with no family history of HSP were also analyzed. All patient samples were screened using denaturing high
performance liquid chromatography (DHPLC) and multiplex ligation-dependent probe amplification (MLPA) assay.
Samples with abnormal DHPLC and MLPA profiles were sequenced, with the same regions sequenced in control
samples.
Results: Sequence variants of SPAST were identified in 19/49 HSP patients (38.8%), twelve among them had
pathogenic mutations. Within the latter group there was one sporadic case. Eight patients had pure, and four -
complex HSP. The twelve variants were identified: seven pathogenic (c.1174-1G>C, c.1185delA, c.1276C>T,
c.1352_1356delGAGAA, c.1378C>A, c.1518_1519insTC, c.1841_1842insA) and five non-pathogenic (c.131C>T,
c.484G>A, c.685A>G, c.1245+202delG, c.1245+215G>C). Only 2 of these mutations had previously been described
(c.131C>T, c.1245+202delG). Three mutations, c.1174-1G>C, c.1276 C>T, c.1378C>A, showed intrafamilial
segregation.
Conclusion: This study identified new variants of the SPAST gene which included benign missense variants and
short insertions/deletions. No large rearrangements were found. Based on these data, 7 new pathogenic variants of
HSP are associated with clinical phenotypes.
Background
Hereditary spastic paraplegia (HSP) comprises a group
of rare neurodegenerative disorders that are character-
ized by progressive spasticity and weakness in the legs.
The prevalence of HSP in European populations has
been reported to vary from 0.5 to 12 individuals per
100,000 [1-4]. For Estonia, a relatively small country
with a population of 1.3 million, the prevalence of HSP
was recently estimated to be 4.4 per 100,000 [5]. Clinical
and genetic heterogeneity, as well as variable severity,
are characteristic features of HSP [6], a disorder which
is further classified as pure (pHSP) or complex (cHSP).
In pHSP, spasticity and motor deficit in the legs, brisk
reflexes, and Babinski’s sign are often accompanied by
deep sensory impairment and sphincter disturbances. In
contrast, a number of neurological and extra-neurologi-
cal features are associated with cHSP which include
ataxia, distal amyotrophy, optic neuropathy, cognitive
impairment, retinopathy, and gastro-oesophageal reflux
[7]. Large inter- and intrafamilial variations in the age of
symptom onset, disease progression, and extent of dis-
ability have also been observed and are typical of this
disorder. Furthermore, HSP can be inherited as an
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(AR-HSP), or rarely, as an X-linked (X-HSP) trait [8].
The number of different loci associated with HSP
includes 18 for AD-HSP, 22 for AR-HSP, and 4 for X-
linked HSP [7,9-11].
Currently, there are over 150 mutations in the entire
SPAST gene (also known as spastin or SPG4)t h a th a v e
been reported to cause at least 40% of all AD-HSP cases
[7,12]. In addition, large-scale rearrangements, such as
exon deletions, are frequently found to cause HSP,
which has been estimated to account for up to 20% of
patients with otherwise mutation-negative HSP [13,14].
The spectrum of mutations associated with HSP is com-
patible with haploinsufficiency being the relevant patho-
genic mechanism for this disorder. In addition, there
have only been a few benign or unclear missense var-
iants in SPG4 and SPG3A associated with unknown
effects [15,16]. Interestingly, missense mutations have
been shown to result in phenotypes that are similar to
those of exon rearrangements [7].
The understanding of genotype-phenotype associations
for HSP is expanding rapidly, and although mutations in
the SPAST gene were previously thought to produce
only AD-pHSP, recent advances in clinicogenetic
research have indicated that the clinical presentation of
HSP can be extremely variable as both sporadic cases
and cHSP forms have been described [17]. Hence, it is
important to expand the available knowledge of HSP.
Accordingly, a recent epidemiological study of HSP
patients in Estonia provided clinical information for a
relatively well-defined population [5]. Therefore, the aim
of this study was to detect mutations present in the
SPAST gene and to characterize the clinical phenotypes
of these patients.
Methods
Study subjects
This study was approved by the Ethics Review Commit-
t e eo nH u m a nR e s e a r c ho ft h eU n i v e r s i t yo fT a r t u ,
Estonia (protocol 110/5, 18.11.2002), and informed con-
sent was obtained from all study participants.
Based on an Estonian epidemiological study that eval-
uated patients diagnosed with HSP between 2001 and
2005 using a multisource approach [5], and previously
described diagnostic criteria for HSP [18,19], 49 patients
were included in this study. Twenty-two of the HSP
patients belonged to 10 different families, while 10
patients had an unconfirmed family history, and 17 were
sporadic cases. All patients were evaluated by at least
two experienced neurologists. Neuropsychological eva-
luations (i.e. Brief Repeatable Battery of Neuropsycholo-
gical Tests, Beck Depression Inventory, Mini-Mental
State Examinations) were performed. Urinary dysfunc-
tion was also evaluated and blood samples were
collected. Healthy individuals (n = 100) with no family
history of HSP those were older than 45 years were
used as population controls. All samples were coded.
Data for the study participants are presented in Table 1.
DNA extraction and analysis of sequence variants
DNA extraction from whole blood was performed using
a High Pure PCR Template Preparation Kit (Roche
Diagnostics GmbH, Mannheim, Germany). Previously
described PCR primers were used for the analysis of the
17 exons and splice sites of the SPAST gene [20]. PCR
products of all 49 samples were screened using denatur-
ing high performance liquid chromatography (DHPLC),
and SPAST copy number aberrations were detected
using multiplex ligation-dependent probe amplification
(MLPA) assays (P165, MRC-Holland, The Netherlands)
as previously described [13]. Only sporadic cases with
normal DHPLC profiles were not sequenced. The same
regions in both HSP and control samples were
sequenced using the BigDye® Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA,
USA). ChromasPro 1.34 http://www.technelysium.com.
au/ChromasPro.html was used for sequence analysis.
Statistical analysis
Differences between patient clinical parameters were
detected using a 2-tailed T-test (Microsoft® Office Excel
2003).
Results
Genetic analysis of the SPAST gene
According to sequencing results, in 19/49 (38.8%) indivi-
duals, 12 nucleotide changes were detected, of which 10
were new (Table 2). All of the individuals were hetero-
zygous for the detected sequence variants without gen-
d e rp r e d i s p o s i t i o n .T h e r ew e r ef i v en o n - p a t h o g e n i ca n d
seven presumably pathogenic variants (mutations). One
new sequence variant, c.1245+215G>C, and a previously
described variant, c.1245+202delG, were detected in
both HSP patients and controls. Therefore, both of
Table 1 Study participant data.
Patients
(n = 49)
Controls
(n = 100)
Gender
Male 32 50
Female 17 50
Mean age
Years (range) 50 (11-75) 64 (45-90)
Nationality
Estonian 39 97
Russian 7 3
Other 3 0
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nucleotide polymorphisms (SNPs). Three pathogenic
mutations, c.1174-1G>C, c.1276 C>T and c.1378C>A,
showed intrafamilial segregation. All other probable
pathogenic mutations (i.e. c.1185delA, c.1352_1356del-
GAGAA, c.1518_1519insTC, and c.1841_1842insA) were
detected in index patients.
Phenotypes of HSP patients with SPAST gene mutations
Pathogenic mutations in the SPAST gene were detected
in 12 individuals diagnosed with HSP (Table 3). Nine
patients with AD-HSP belonged to four different pedi-
grees: patients 2109, 2930 and 2931 to pedigree I,
patients 2480 and 2482 to pedigree II, patients 2833,
2747 and 2754 to pedigree III and patient 2389 to pedi-
gree IV. There was one clinically confirmed sporadic
case (patient 2478). Two subjects with HSP had an
unconfirmed family history (patients 2752 and 2753).
Patient 2753 was a Russian male with a brother living
abroad that exhibited the same walking pattern yet had
not been evaluated by neurologists and therefore had
not been diagnosed with HSP. Yet another patient was
an Armenian male (patient 2752) with an unconfirmed
family history of HSP and potentially affected relatives
living abroad.
All patients with pathogenic mutations in the SPAST
gene exhibited progressive spastic paraparesis, with 8
patients, including the sporadic patient case, also experi-
encing bladder disturbances (66%) and 9 having mild or
moderate degree of depression (75%). Furthermore, 8
patients with pathogenic SPAST mutations had pHSP
and 4 were diagnosed with cHSP and exhibited different
degrees of cognitive impairment (33%). There were 3
patients having both - cognitive decline and bladder dis-
turbances (25%) and they were also depressed.
Two females from pedigree III used assistive devices: a
59-year-old patient (2388) used a cane, and a 40-year-
old patient (2754) used bilateral crutches. In addition,
an Armenian patient (2752) experienced severe neurolo-
gical effects from cHSP and required a wheelchair, a 70-
year-old male (2478) was classified as a sporadic case
and used a cane for walking, while a 57-year-old female
(patient 2480 from pedigree II) with pHSP had pes
cavus and used a unilateral cane. The remaining patients
(2109, 2389, 2482, 2747, 2753, 2930, and 2931) walked
independently.
Discussion
Mutations in the SPAST gene are the most common
genetic abnormality associated with HSP. In this study,
12 changes in the SPAST gene were identified, 7 of
which represented new pathogenic variants and 2 were
previously described. Both missense mutations in the
exons (amino acid change) and frameshift mutations
(formation of new stop codon) were predominantly
identified, which have the potential to alter the protein
structure of SPAST. Changes in splice sites are also
important and can lead to exon skipping and a reduced
stability for aberrantly spliced mRNAs [21,22]. Interest-
ingly, no single deletion or duplication of an exon was
Table 2 Description of SPAST gene variants identified in individuals with HSP.
Variant
# Identified by Location Predicted effect at
the protein level
#
Present in
(49 patients/
100 controls)
Patients Intrafamilial
segregation
Inferred
pathogeneity
c.131C>T* S exon 1 p.S44L 2/0 2942, 2943 - NP
c.484G>A DHPLC/S exon 2 p.V162I 3/0 2627, 2747, 2943 - NP
c.685A>G DHPLC/S exon 5 p.S229G 1/0 2930 - NP
c.1174-1G>C S intron 8 missplicing
(deletion
exon 9?)
3/0 2109, 2930, 2931 Yes P
c.1185delA DHPLC/S exon 9 p.V385VfsX11 1/0 2752 - P
c.1276 C>T S exon 10 p.L426F 3/0 2388, 2747, 2754 Yes P
c.1245+202delG* S intron 10 none 3/4 2321, 2386, 2750 - NP
c.1245+215G>C S intron 10 none 1/2 2960 - NP
c.1352_1356del
GAGAA
DHPLC/MLPA/S exon 11 p.R451RfsX5 1/0 2753 - P
c.1378C>A DHPLC/S exon 11 p.R460S 2/0 2480, 2482 Yes P
c.1518_1519insTC MLPA/S exon 13 p.S507SfsX23 1/0 2478 - P
c.1841_1842insA DHPLC/S exon17 p.T614NfsX
no Stop codon
1/0 2389 - P
#nomenclature according to HGVS http://www.hgvs.org/mutnomen/; *previously described; DHPLC - denaturing high performance liquid chromatography; MLPA -
multiplex ligation-dependent probe amplification; S - sequencing; P - pathogenic; NP - non-pathogenic.
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sidering our identification of seven pathogenic “small”
mutations, one could have expected to find several exo-
nic rearrangements. The lack of this kind of mutations
is hypothesized to be a unique aspect of the Estonian
HSP population. A presence in additional patients, how-
ever, cannot be excluded.
There were 5 non-pathogenic variants in our study
group. Two out of three members (patients 2942 and
2943) of one family without pathogenic SPAST muta-
tions had a substitution c.131C>T. It has previously
been suggested that c.131C>T is a benign SNP, yet
represents an aggravating disease modifier, since it is
usually associated with a pathogenic variant [23,24].
One previously described variant, c.1245+202delG, was
identified as a SNP in the HSP patients analyzed as well
as in controls [25]. Another sequence variant, c.1245
+215G>C, was not previously reported, but since it was
detected in both patients and controls, it is also
hypothesized to be a SNP. We would also hypothesize
that c.484G>A and c.685A>G represent benign missense
variants that are rare and specific to the Estonian
population.
In our study group, 2 families contained 2 variants in
their SPAST gene. For a 33-year-old man with AD-
cHSP (patient 2747 from pedigree III), his two affected
relatives (his sister and mother - patients 2754 and
2388, respectively) did not have the same sequence var-
iants present in exon 2, yet all affected members of this
family had a mutation present in exon 10. Also in one
49-year-old woman (patient 2930 from pedigree I) two
variants were found - like two of her relatives with HSP
(sister and daughter - patients 2109 and 2931 respec-
tively), she had a splicing mutation at the border of
i n t r o n8 / e x o n9o ft h eSPAST gene, but additionally a
change in exon 5. Hence, these two families contain two
mutations in their SPAST gene, one of which is
hypothesized to be de novo or a rare SNP. The lack of
family segregation of the variants in these pedigrees may
be indicative of the non-pathogenic effect of the mis-
sense mutations detected in exons 1, 2, and 5 in the
Estonian population.
The present study describes phenotypes of HSP
patients with SPAST gene mutations. By comparing
patient phenotypes, the average age of symptom onset
for Estonian patients with SPAST mutations was deter-
mined to be 27.8 years (range 3-46), while in other
patients with HSP it was 30.0 years (range 5-69) [5].
The mean difference in the age of onset between the
two groups was 2.2 years, which was not determined to
be significant. Similarly, for previously published data on
356 patients with known mutations in the SPAST gene,
no correlation between the age of onset and the type of
mutation present could be identified [26]. There was no
gender predisposition for patients with SPAST muta-
tions, which included 5 males and 7 females. Previous
reports regarding gender have been inconsistent,
although studies of large Brazilian pedigrees have found
Table 3 Phenotypes of HSP patients with pathogenic SPAST mutations.
Patient Gender Nationality Clinical form
of HSP
Age of onset
(years)
Additional clinical description Pedigree Variant
2109 F Estonian AD-cHSP 30 Bladder dysfunction, mild dementia, mild
depression
I c.1174-1G>C
2930 F Estonian AD-pHSP 35 Bladder dysfunction, mild depression I
2931 F Estonian AD-pHSP 10 - I
2480 F Estonian AD-pHSP 28 Bladder dysfunction, pes cavus, moderate
depression, uses cane
II c.1378C>A
2482 M Estonian AD-pHSP 3 Mild depression II
2388 F Estonian AD-pHSP 40 Bladder dysfunction, mild depression, uses
cane
III c.1276 C>T
2747 M Estonian AD-cHSP 21 Mild cognitive impairment, moderate
depression
III
2754 F Estonian AD-pHSP 12 Bladder dysfunction, mild depression, uses
bilateral crutches
III
2389 F Estonian AD-cHSP 46 Bladder dysfunction, mild cognitive
impairment, mild depression
IV c.1841_1842insA
2753 M Russian pHSP 36 - NA c.1352_1356del
GAGAA
2752 M Armenian cHSP 38 Bladder dysfunction,
mild cognitive impairment, mild depression,
uses wheelchair
NA c.1185delA
2478 M Estonian pHSP 35 Sporadic case, bladder dysfunction, uses cane NA c.1518_1519insTC
F - female; M - male; HSP - hereditary spastic paraplegia; pHSP - pure HSP; cHSP - complex HSP; AD - autosomal dominant; NA - not applicable.
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The patients with mutations in the SPAST gene are less
likely to have cHSP, and these data further imply that
all patients with HSP should be preferentially tested for
SPAST mutations. Neurologic co-symptoms associated
with patients with SPAST mutations were mainly blad-
der disturbances, cognitive impairment and depression,
being discussed in detail elsewhere [29,30]. Compared
with previous reports of HSP patients with bladder dys-
function, only a few other authors described a similar
co-existence for HSP with neuropsychological symptoms
[19]. The clinical relevance of these observations is that
patients with SPAST mutations should receive a more
thorough neurological evaluation so that co-symptoms
are diagnosed adequately since their symptoms can
often be effectively treated.
The limitations of this study should also be consid-
ered. For example, samples from all HSP patients identi-
fied in the Estonian population studied were unable to
be sequenced, which would have increased the confi-
dence of the conclusions of this study. Furthermore, the
use of DHPLC to detect changes in the SPAST gene did
not reliably identify all of the individuals with abnormal
profiles. For example the MLPA assay detected two base
pair insertions which were not detected by DHPLC.
These differences were confirmed by sequencing. Hence,
SPAST variants, especially among sporadic cases, could
be missed if DHPLC is the only detection method used.
In addition, although healthy controls without any his-
tory of HSP in their pedigrees were included in this
study, it is still theoretically possible that these controls
could develop symptoms of HSP when they are older,
although it is extremely unlikely.
Conclusions
In conclusion, the present study describes novel muta-
tions in the SPAST gene of HSP patients, thereby con-
firming the genetic variability associated with this
disorder. A lack of exon deletions/duplications and the
presence of rare coding SNPs differentiate this Estonian
study group from others previously reported in the lit-
erature. Due to the large clinical and genetic variabilities
observed [31], and the absence of strict genotype-pheno-
type correlations, we suggest that in the clinical setting
it is insufficient to test individuals with HSP for only
known SPAST mutations, and in the case of negative
results, additional loci should be sequenced in case
other HSP mutations may be present.
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